@article{Kuusanmäki_Kytölä_Vänttinen_Ruokoranta_Ranta_Huuhtanen_Suvela_Parsons_Holopainen_Partanen_Kuusisto_Koskela_Räty_Itälä-Remes_Västrik_Dufva_Siitonen_Porkka_Wennerberg_Heckman_Ettala_Pyörälä_Rimpiläinen_Siitonen_Kontro_2023, place={Pavia, Italy}, title={<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia}, volume={108}, url={https://haematologica.org/article/view/haematol.2022.281692}, DOI={10.3324/haematol.2022.281692}, abstractNote={<p>The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly for relapsed or refractory AML. Ex vivo drug sensitivity testing may correlate with outcomes, but its prospective predictive value remains unexplored. Here we report the results of the first stage of the prospective phase II VenEx trial evaluating the utility and predictiveness of venetoclax sensitivity testing using different cell culture conditions and cell viability assays in patients receiving venetoclax-azacitidine. Participants with de novo AML ineligible for intensive chemotherapy, relapsed or refractory AML, or secondary AML were included. The primary endpoint was the treatment response in participants showing ex vivo sensitivity and the key secondary endpoints were the correlation of sensitivity with responses and survival. Venetoclax sensitivity testing was successful in 38/39 participants. Experimental conditions significantly influenced the predictive accuracy. Blast-specific venetoclax sensitivity measured in conditioned medium most accurately correlated with treatment outcomes; 88% of sensitive participants achieved a treatment response. The median survival was significantly longer for participants who were ex vivo-sensitive to venetoclax (14.6 months for venetoclax-sensitive patients vs. 3.5 for venetoclax-insensitive patients, P&lt;0.001). This analysis illustrates the feasibility of integrating drug-response profiling into clinical practice and demonstrates excellent predictivity. This trial is registered with ClinicalTrials.gov identifier: NCT04267081.</p&gt;}, number={7}, journal={Haematologica}, author={Kuusanmäki, Heikki and Kytölä, Sari and Vänttinen, Ida and Ruokoranta, Tanja and Ranta, Amanda and Huuhtanen, Jani and Suvela, Minna and Parsons, Alun and Holopainen, Annasofia and Partanen, Anu and Kuusisto, Milla E.L. and Koskela, Sirpa and Räty, Riikka and Itälä-Remes, Maija and Västrik, Imre and Dufva, Olli and Siitonen, Sanna and Porkka, Kimmo and Wennerberg, Krister and Heckman, Caroline A. and Ettala, Pia and Pyörälä, Marja and Rimpiläinen, Johanna and Siitonen, Timo and Kontro, Mika}, year={2023}, month={Jul.}, pages={1768-1781} }